NeoGenomics (NEO) reported $151.95 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 18%. EPS of $0.00 for the same period compares to -$0.14 a year ago.
The reported revenue represents a surprise of +6.90% over the Zacks Consensus Estimate of $142.15 million. With the consensus EPS estimate being -$0.06, the EPS surprise was +100.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company’s financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock’s price performance.
Here is how NeoGenomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Clinical – Number of tests performed: 289,637 versus 286,725 estimated by three analysts on average.
- Clinical – Average revenue/test: $0.44 compared to the $0.41 average estimate based on three analysts.
- Revenue- Advanced Diagnostics: $24.40 million compared to the $23.55 million average estimate based on four analysts. The reported number represents a change of +7.9% year over year.
- Revenue- Clinical Services: $127.55 million versus the four-analyst average estimate of $118.81 million. The reported number represents a year-over-year change of +20.2%.
- Gross Profit- Advanced Diagnostics: $8.75 million versus the three-analyst average estimate of $8.77 million.
- Gross Profit- Clinical Services: $53.56 million compared to the $52.28 million average estimate based on three analysts.
View all Key Company Metrics for NeoGenomics here>>>
Shares of NeoGenomics have returned +26.6% over the past month versus the Zacks S&P 500 composite’s +3.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Zacks Reveals ChatGPT “Sleeper” Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other “must buys.” Plus more.
Download Free ChatGPT Stock Report Right Now >>
NeoGenomics, Inc. (NEO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.